SEC Form 4/A · accession 0001179110-18-012203
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Christopher P Leamon
Officer — Vice President of Research
Period of report
Oct 5, 2018
Accepted (ET)
Oct 16, 2018 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Oct 5, 2018 | S | 9,028 | $15.5557 | D | 122,219 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the sale of 9,028 shares in multiple transactions, ranging in price from $15.1300 to $15.9200, resulting in a weighted-average sale price per share of $15.5557. The 9,028 shares were sold to cover taxes, commissions and fees associated with the October 4, 2018 settlement of 20,000 restricted stock units in the form of Company common stock on a one-for-one basis. The shares were sold pursuant to a written plan as specified in Rule 10b5-1(c) of the Securities Exchange Act of 1934.
- F2Includes 866 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on June 15, 2018 that were inadvertently omitted from the amount of securities beneficially owned by the reporting person as reported on subsequent Form 4s.